Prostate cancer patients covered by the National Hospital Insurance Fund (NHIF) can now access a new drug that enhances treatment.
The drug, Abiraterone Acetate, from Janssen Kenya, is used for treating advanced prostate cancer and will be available to NHIF members within their benefits package after an agreement between NHIF and Janssen Kenya.